



## OPEN ACCESS

## EDITED AND REVIEWED BY

Arturo Anadón,  
Complutense University of Madrid, Spain

## \*CORRESPONDENCE

Jiyu Zhang  
✉ infzjy@sina.com

## SPECIALTY SECTION

This article was submitted to  
Veterinary Pharmacology and Toxicology,  
a section of the journal  
Frontiers in Veterinary Science

RECEIVED 23 December 2022

ACCEPTED 13 January 2023

PUBLISHED 01 February 2023

## CITATION

Wang W, Dong Z, Zhang J, Zhou X, Wei X,  
Cheng F, Li B and Zhang J (2023) Corrigendum:  
Acute and subacute toxicity assessment of  
oxyclozanide in Wistar rats.  
*Front. Vet. Sci.* 10:1130466.  
doi: 10.3389/fvets.2023.1130466

## COPYRIGHT

© 2023 Wang, Dong, Zhang, Zhou, Wei, Cheng,  
Li and Zhang. This is an open-access article  
distributed under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#). The use,  
distribution or reproduction in other forums is  
permitted, provided the original author(s) and  
the copyright owner(s) are credited and that  
the original publication in this journal is cited, in  
accordance with accepted academic practice.  
No use, distribution or reproduction is  
permitted which does not comply with these  
terms.

# Corrigendum: Acute and subacute toxicity assessment of oxyclozanide in Wistar rats

Weiwei Wang<sup>1,2,3</sup>, Zhen Dong<sup>1,2,3</sup>, Jili Zhang<sup>1,2,3</sup>, Xuzheng Zhou<sup>1,2,3</sup>,  
Xiaojuan Wei<sup>1,2,3</sup>, Fusheng Cheng<sup>1,2,3</sup>, Bing Li<sup>1,2,3</sup> and Jiyu Zhang<sup>1,2,3\*</sup>

<sup>1</sup>Key Laboratory of New Animal Drug Project of Gansu Province, Lanzhou, China, <sup>2</sup>Key Laboratory of Veterinary Pharmaceutical Development, Ministry of Agriculture, Lanzhou, China, <sup>3</sup>Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, China

## KEYWORDS

oxyclozanide, acute, subacute, toxicity, rats

## A corrigendum on

### Acute and subacute toxicity assessment of oxyclozanide in Wistar rats

by Wang, W., Dong, Z., Zhang, J., Zhou, X., Wei, X., Cheng, F., Li, B., and Zhang, J. (2019). *Front. Vet. Sci.* 6:294. doi: 10.3389/fvets.2019.00294

In the published article Reference Manual of Laboratory Animal Blood Physiology and Biochemistry (*book*) was not cited in the article. The citation has now been inserted in [Tables 2, 3](#), [Historical controls range] and should read:

“[Historical controls range (45)]”

45. Wang D, Zeng L, Shang S. *Reference Manual of Laboratory Animal Blood Physiology and Biochemistry*. Science Publishing (2011).

In the published article, there was an error in [Table 2](#) as published. The units for the hematological parameters used in [Table 2](#) were missing. The corrected [Table 2](#) and its caption \*\*Hematological values of rats in the oxyclozanide-treated group and the control group appear below.

In the published article, there was an error in [Table 3](#) as published. The units for the biochemical parameters used in [Table 3](#) were missing. The corrected [Table 3](#) and its caption \*\*Liver function related to biochemical profiles appear below.

In the published article, **Supplementary Appendix 1** was mistakenly not included in the publication. The missing material appears below:

The blood samples collected in the EDTAK2-coated tubes were analyzed using Mindray BC-2800 Vet Automatic blood analyser (MINDRAY Medical International Co., Ltd). Erba XL-640 Automatic biochemical analyser (Erba Mannheim Co., Ltd.) was used for biochemical examination.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 2 Haematological values of rats in oxyclozanide-treated group and control group.

	Historical controls range (45)	Oxyclozanide doses (mg/kg)			
		0 mg/kg (control)	74 mg/kg (low-dose)	185 mg/kg (medium-dose)	370 mg/kg (high-dose)
<b>Male</b>					
WBC ( $\times 10^9 \cdot L^{-1}$ )	4–6	5.28 $\pm$ 2.12	4.00 $\pm$ 1.73	5.47 $\pm$ 2.44	5.13 $\pm$ 1.22
LYM ( $\times 10^9 \cdot L^{-1}$ )	2–5	2.87 $\pm$ 1.70	3.50 $\pm$ 1.22	4.10 $\pm$ 2.01	3.88 $\pm$ 0.96
Mon ( $\times 10^9 \cdot L^{-1}$ )	0.05–0.10	0.05 $\pm$ 0.071	0.06 $\pm$ 0.074	0.08 $\pm$ 0.071	0.08 $\pm$ 0.044
Gran ( $\times 10^9 \cdot L^{-1}$ )	0.5–1.0	0.54 $\pm$ 0.46	0.63 $\pm$ 0.43	0.80 $\pm$ 0.48	0.98 $\pm$ 0.48
RBC ( $\times 10^{12} \cdot L^{-1}$ )	6–8	7.04 $\pm$ 0.38	7.29 $\pm$ 0.51	7.03 $\pm$ 0.48	6.93 $\pm$ 0.45
HGB (g·L <sup>-1</sup> )	120–140	137.55 $\pm$ 5.47	128.60 $\pm$ 22.83	135.38 $\pm$ 10.21	136.17 $\pm$ 10.53
HCT	35–45	41.57 $\pm$ 1.50	43.14 $\pm$ 3.10	41.26 $\pm$ 3.02	41.18 $\pm$ 3.11
MCV (fL)	55–65	59.16 $\pm$ 1.91	59.24 $\pm$ 0.97	58.75 $\pm$ 1.88	59.47 $\pm$ 2.32
MCH (pg)	17–21	19.51 $\pm$ 0.48	17.37 $\pm$ 3.01**	19.18 $\pm$ 0.46	19.58 $\pm$ 0.67
MCHC (g·L <sup>-1</sup> )	270–340	330.36 $\pm$ 4.39	293.67 $\pm$ 50.54	327.50 $\pm$ 7.44	330.17 $\pm$ 7.98
RDW	10–15	11.60 $\pm$ 2.21	10.84 $\pm$ 1.69	12.75 $\pm$ 1.84	12.60 $\pm$ 1.81
PLT ( $\times 10^9 \cdot L^{-1}$ )	800–1,000	860.18 $\pm$ 153.11	939.44 $\pm$ 154.04	956.38 $\pm$ 68.66	759.40 $\pm$ 144.87
MPV (fL)	5–7	6.38 $\pm$ 0.25	6.28 $\pm$ 0.31	6.09 $\pm$ 0.50	5.95 $\pm$ 0.66
PDW	15–17	16.19 $\pm$ 0.18	16.29 $\pm$ 0.32	16.13 $\pm$ 0.25	16.22 $\pm$ 0.43
PCT (ng·L <sup>-1</sup> )	0.4–0.8	0.53 $\pm$ 0.079	0.56 $\pm$ 0.073	0.58 $\pm$ 0.052	0.58 $\pm$ 0.090
<b>Female</b>					
WBC ( $\times 10^9 \cdot L^{-1}$ )	4–6	4.14 $\pm$ 2.16	5.76 $\pm$ 1.63	4.66 $\pm$ 1.98	5.01 $\pm$ 1.36
LYM ( $\times 10^9 \cdot L^{-1}$ )	3–5	3.46 $\pm$ 1.55	4.64 $\pm$ 0.612	4.25 $\pm$ 1.09	4.11 $\pm$ 1.14
Mon ( $\times 10^9 \cdot L^{-1}$ )	0.05–0.10	0.09 $\pm$ 0.074	0.10 $\pm$ 0.076	0.08 $\pm$ 0.067	0.06 $\pm$ 0.052
Gran ( $\times 10^9 \cdot L^{-1}$ )	0.6–1.1	0.86 $\pm$ 0.45	0.90 $\pm$ 0.41	1.00 $\pm$ 0.42	0.92 $\pm$ 0.20
RBC ( $\times 10^{12} \cdot L^{-1}$ )	6–8	7.45 $\pm$ 0.21	7.21 $\pm$ 1.31	7.26 $\pm$ 1.47	7.23 $\pm$ 0.35
HGB (g·L <sup>-1</sup> )	120–140	148.45 $\pm$ 7.85	126.38 $\pm$ 28.23	136.80 $\pm$ 38.84	143.88 $\pm$ 6.94
HCT	35–45	44.50 $\pm$ 1.22	42.80 $\pm$ 7.84	42.99 $\pm$ 8.63	43.70 $\pm$ 2.07
MCV (fL)	60 $\pm$ 6	59.86 $\pm$ 1.73	53.05 $\pm$ 19.12	59.30 $\pm$ 1.00	60.55 $\pm$ 2.37
MCH (pg)	17–21	19.89 $\pm$ 0.81	17.53 $\pm$ 2.35*	18.44 $\pm$ 3.49	19.88 $\pm$ 0.69
MCHC (g·L <sup>-1</sup> )	270–340	333.00 $\pm$ 15.50	296.13 $\pm$ 41.19*	311.78 $\pm$ 58.95	328.88 $\pm$ 4.12
RDW	10–15	14.92 $\pm$ 0.45	13.80 $\pm$ 1.16**	14.78 $\pm$ 0.55	14.41 $\pm$ 0.77
PLT ( $\times 10^9 \cdot L^{-1}$ )	900–1,100	1,015.82 $\pm$ 91.63	970.38 $\pm$ 215.43	921.38 $\pm$ 192.32	953.33 $\pm$ 155.58
MPV (fL)	5–7	6.25 $\pm$ 0.22	6.33 $\pm$ 0.26	6.46 $\pm$ 0.69	6.18 $\pm$ 0.37
PDW	15–17	16.07 $\pm$ 0.13	16.13 $\pm$ 0.18	16.50 $\pm$ 1.15	16.10 $\pm$ 0.41
PCT (ng·L <sup>-1</sup> )	0.4–0.8	0.63 $\pm$ 0.056	0.55 $\pm$ 0.132*	0.49 $\pm$ 0.174	0.50 $\pm$ 0.197

\* $p < 0.05$  vs. control group.\*\* $p < 0.01$  vs. control group.

TABLE 3 Liver function related to biochemical profiles.

	Historical controls range (45)	Oxyclozanide doses			
		0 mg/kg (Control)	74 mg/kg (Low-dose)	185 mg/kg (Medium-dose)	370 mg/kg (High-dose)
<b>Male</b>					
TBIL ( $\mu\text{mol}\cdot\text{L}^{-1}$ )	0.3–0.7	0.52 $\pm$ 0.23	0.54 $\pm$ 0.29	0.39 $\pm$ 0.19	0.35 $\pm$ 0.17
DBIL ( $\mu\text{mol}\cdot\text{L}^{-1}$ )	0.8–1.4	1.20 $\pm$ 0.55	0.97 $\pm$ 0.32	1.01 $\pm$ 0.22	1.32 $\pm$ 0.51
TP ( $\text{g}\cdot\text{L}^{-1}$ )	30–50	41.94 $\pm$ 15.15	36.17 $\pm$ 11.22	41.83 $\pm$ 9.38	49.97 $\pm$ 8.13
ALB ( $\text{g}\cdot\text{L}^{-1}$ )	18–26	19.45 $\pm$ 6.61	18.30 $\pm$ 5.53	19.63 $\pm$ 4.04	24.36 $\pm$ 3.48*
GLO ( $\text{g}\cdot\text{L}^{-1}$ )	16–26	22.45 $\pm$ 8.63	17.87 $\pm$ 5.73	22.20 $\pm$ 5.57	25.62 $\pm$ 4.90
ALT ( $\text{U}\cdot\text{L}^{-1}$ )	25–35	34.88 $\pm$ 12.47	27.35 $\pm$ 9.97	34.62 $\pm$ 9.68	32.45 $\pm$ 5.23
AST ( $\text{U}\cdot\text{L}^{-1}$ )	95–150	98.43 $\pm$ 33.86	132.14 $\pm$ 35.72	158.11 $\pm$ 48.63**	199.45 $\pm$ 32.55**
ALP ( $\text{U}\cdot\text{L}^{-1}$ )	120–200	131.71 $\pm$ 25.22	135.00 $\pm$ 26.93	197.00 $\pm$ 46.29*	224.00 $\pm$ 81.28**
TG ( $\text{mmol}\cdot\text{L}^{-1}$ )	0.5–0.7	0.62 $\pm$ 0.18	0.63 $\pm$ 0.17	0.68 $\pm$ 0.33	0.56 $\pm$ 0.16
TC ( $\text{mmol}\cdot\text{L}^{-1}$ )	1.0–2.0	1.52 $\pm$ 0.47	1.34 $\pm$ 0.45	1.70 $\pm$ 0.36	1.70 $\pm$ 0.36
GLU ( $\text{mmol}\cdot\text{L}^{-1}$ )	4–8	6.64 $\pm$ 1.50	6.00 $\pm$ 1.15	5.49 $\pm$ 1.45	4.95 $\pm$ 1.09**
BUN ( $\text{mmol}\cdot\text{L}^{-1}$ )	5–9	5.49 $\pm$ 1.34	7.01 $\pm$ 1.98	7.17 $\pm$ 1.33	8.76 $\pm$ 2.99**
CR ( $\mu\text{mol}\cdot\text{L}^{-1}$ )	20–30	24.89 $\pm$ 17.67	21.05 $\pm$ 7.06	25.22 $\pm$ 5.19	29.46 $\pm$ 8.73
UA ( $\mu\text{mol}\cdot\text{L}^{-1}$ )	0.04–0.06	0.046 $\pm$ 0.012	0.045 $\pm$ 0.017	0.065 $\pm$ 0.021	0.080 $\pm$ 0.048*
LDH ( $\text{U}\cdot\text{L}^{-1}$ )	1,200–2,000	1,320.30 $\pm$ 469.50	1,582.11 $\pm$ 303.31	1,864.00 $\pm$ 433.37**	1,954.77 $\pm$ 236.24**
CK ( $\text{U}\cdot\text{L}^{-1}$ )	1,100–1,700	1,188.72 $\pm$ 488.39	1,210.48 $\pm$ 279.84	1,499.38 $\pm$ 405.02	1,628.94 $\pm$ 312.20**
<b>Female</b>					
TBIL ( $\mu\text{mol}\cdot\text{L}^{-1}$ )	0.4–0.8	0.69 $\pm$ 0.27	0.45 $\pm$ 0.26*	0.49 $\pm$ 0.14	0.27 $\pm$ 0.12**
DBIL ( $\mu\text{mol}\cdot\text{L}^{-1}$ )	1–2	1.32 $\pm$ 0.42	1.27 $\pm$ 0.47	1.46 $\pm$ 0.49	1.48 $\pm$ 0.43
TP ( $\text{g}\cdot\text{L}^{-1}$ )	40–48	45.85 $\pm$ 9.98	42.24 $\pm$ 10.40	45.40 $\pm$ 13.24	40.32 $\pm$ 4.21
ALB ( $\text{g}\cdot\text{L}^{-1}$ )	20–26	23.33 $\pm$ 4.65	21.60 $\pm$ 5.10	22.49 $\pm$ 6.09	25.87 $\pm$ 3.98
GLO ( $\text{g}\cdot\text{L}^{-1}$ )	20–30	22.52 $\pm$ 5.34	20.65 $\pm$ 5.36	22.91 $\pm$ 7.30	28.97 $\pm$ 6.49**
ALT ( $\text{U}\cdot\text{L}^{-1}$ )	25–35	26.11 $\pm$ 7.17	25.64 $\pm$ 10.56	30.68 $\pm$ 11.99	33.92 $\pm$ 6.11
AST ( $\text{U}\cdot\text{L}^{-1}$ )	130–180	137.10 $\pm$ 31.18	155.70 $\pm$ 39.79	177.71 $\pm$ 49.51*	206.60 $\pm$ 25.16**
ALP ( $\text{U}\cdot\text{L}^{-1}$ )	90–140	97.82 $\pm$ 31.68	122.00 $\pm$ 30.99	146.17 $\pm$ 23.81**	190.67 $\pm$ 21.56**
TG ( $\text{mmol}\cdot\text{L}^{-1}$ )	0.5–1.0	0.76 $\pm$ 0.25	0.56 $\pm$ 0.14*	0.54 $\pm$ 0.17*	0.45 $\pm$ 0.06**
TC ( $\text{mmol}\cdot\text{L}^{-1}$ )	1.0–2.0	1.54 $\pm$ 0.29	1.59 $\pm$ 0.35	1.64 $\pm$ 0.43	1.73 $\pm$ 0.22
GLU ( $\text{mmol}\cdot\text{L}^{-1}$ )	4–8	5.73 $\pm$ 1.33	5.59 $\pm$ 0.68	5.86 $\pm$ 2.01	4.62 $\pm$ 0.61
BUN ( $\text{mmol}\cdot\text{L}^{-1}$ )	5–10	5.75 $\pm$ 2.14	8.30 $\pm$ 1.94**	7.95 $\pm$ 1.58*	9.63 $\pm$ 1.59**
CR ( $\mu\text{mol}\cdot\text{L}^{-1}$ )	25–30	27.02 $\pm$ 6.23	25.96 $\pm$ 6.94	26.28 $\pm$ 6.42	28.80 $\pm$ 5.45
UA ( $\mu\text{mol}\cdot\text{L}^{-1}$ )	0.05–0.07	0.061 $\pm$ 0.016	0.056 $\pm$ 0.011	0.071 $\pm$ 0.034	0.063 $\pm$ 0.020
LDH ( $\text{U}\cdot\text{L}^{-1}$ )	1,200–1,800	1,605.75 $\pm$ 278.48	1,802.50 $\pm$ 342.99	1,840.88 $\pm$ 343.80	1,895.00 $\pm$ 195.69
CK ( $\text{U}\cdot\text{L}^{-1}$ )	1,100–1,700	1,306.00 $\pm$ 309.40	1,547.52 $\pm$ 369.63	1,595.46 $\pm$ 323.62	1,503.43 $\pm$ 192.21

\*\* $p < 0.01$  vs. control group.\* $p < 0.05$  vs. control group.